肝脏 ›› 2023, Vol. 28 ›› Issue (1): 1-10.
• 指南与共识 • 下一篇
国际肝胆胰协会中国分会中国抗癌协会肝癌专业委员会 中国研究型医院肝胆外科专业委员会 中国研究型医院病毒与肿瘤专业委员会
收稿日期:2022-12-24
出版日期:2023-01-31
发布日期:2023-02-21
通讯作者:
陈孝平,华中科技大学同济医学院附属同济医院 武汉 430030,Email:chenxpchenxp@163.com;樊嘉,复旦大学附属中山医院 上海 200032,Email:fan.jia@zs?hospital.sh.cn;董家鸿,北京清华长庚医院 北京100073,Email:dongjiahong@ mail.tsinghua.edu.cn;李欣,南方医科大学深圳医院 深圳 518100,Email:lixin@smu.edu.cn;陈成伟,解放军海军第905医院 上海200235,Email:ccw2@188.com;周伟平,海军军医大学附属东方肝胆外科医院 上海 200438,Email:ehphwp@ 126.com
Received:2022-12-24
Online:2023-01-31
Published:2023-02-21
国际肝胆胰协会中国分会中国抗癌协会肝癌专业委员会 中国研究型医院肝胆外科专业委员会 中国研究型医院病毒与肿瘤专业委员会. 乙型肝炎病毒相关肝细胞癌抗病毒治疗中国专家共识(2023年版)[J]. 肝脏, 2023, 28(1): 1-10.
| [1] Akinyemiju T, Abera S, Ahmed M, et al. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol, 2017,3(12):1683-1691. [2] McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis, 2015,19(2):223-238. [3] Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2019,394(10204):1145-1158. [4] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016,66(2):115-132. [5] https://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf. [6] de Martel C, Maucort-Boulch D, Plummer M, et al. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology, 2015,62(4):1190-1200. [7] 中国原发性肝癌临床登记调查(CLCS)的中期报告. http://mini.eastday.com/a/191010151730524.html 2020 年中国临床肿瘤学大会暨 CSCO 学术年会. [8] Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med, 2004,351(15):1521-1531. [9] Lim YS, Han S, Heo NY, et al. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine. Gastroenterology, 2014,147(1):152-161. [10] Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet, 2013,381(9865):468-475. [11] Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology, 2010,52(3):886-893. [12] Wong GL, Chan HL, Mak CW, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology, 2013,58(5):1537-1547. [13] Chan AC, Chok KS, Yuen WK, et al. Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma. Arch Surg, 2011,146(6):675-681. [14] Wu CY, Chen YJ, Ho HJ, et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA, 2012,308(18):1906-1914. [15] Huang G, Lau WY, Wang ZG, et al. Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial. Ann Surg, 2015,261(1):56-66. [16] Huang G, Li PP, Lau WY, et al. Antiviral Therapy Reduces Hepatocellular Carcinoma Recurrence in Patients With Low HBV-DNA Levels: A Randomized Controlled Trial. Ann Surg, 2018,268(6):943-954. [17] Wong GL, Tse YK, Chan HL, et al. Oral nucleos(t)ide analogues reduce recurrence and death in chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther, 2016,43(7):802-813. [18] Yin J, Li N, Han Y, et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol, 2013,31(29):3647-3655. [19] Hung IF, Wong DK, Poon RT, et al. Risk Factors and Post-Resection Independent Predictive Score for the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma. PLoS One, 2016,11(2):e0148493. [20] 中华医学会感染病学分会,中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版). 临床肝胆病杂志,2019,35(12):2648-2669. [21] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版). 临床肝胆病杂志,2020,36(2):277-292. [22] Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol,2011,64(4):383-394. [23] Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol,2011,64(4):401-406. [24] Andrews JC, Schünemann HJ, Oxman AD, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. J Clin Epidemiol,2013,66(7):726-735. [25] ASCO Guidelines Methodology Manual. 2021. Accessed online via: https://www.asco.org/practice-patients/guidelines/guideline-methodology [26] Li Z, Zhao X, Jiang P, et al. HBV is a risk factor for poor patient prognosis after curative resection of hepatocellular carcinoma: A retrospective case-control study. Medicine (Baltimore), 2016,95(31):e4224. [27] Qu LS, Jin F, Huang XW, et al. High hepatitis B viral load predicts recurrence of small hepatocellular carcinoma after curative resection. J Gastrointest Surg, 2010,14(7):1111-1120. [28] Goto T, Yoshida H, Tateishi R, et al. Influence of serum HBV DNA load on recurrence of hepatocellular carcinoma after treatment with percutaneous radiofrequency ablation. Hepatol Int, 2011,5(3):767-773. [29] Hung IF, Poon RT, Lai CL, et al. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol, 2008,103(7):1663-1673. [30] Yang T, Lu JH, Zhai J, et al. High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study. Eur J Surg Oncol, 2012,38(8):683-691. [31] Huang G, Lau WY, Shen F, et al. Preoperative hepatitis B virus DNA level is a risk factor for postoperative liver failure in patients who underwent partial hepatectomy for hepatitis B-related hepatocellular carcinoma. World J Surg, 2014,38(9):2370-2376. [32] Kim TS, Sinn DH, Kang W, et al. Hepatitis B virus DNA levels and overall survival in hepatitis B-related hepatocellular carcinoma patients with low-level viremia. J Gastroenterol Hepatol, 2019,34(11):2028-2035. [33] Sohn W, Paik YH, Kim JM, et al. HBV DNA and HBsAg levels as risk predictors of early and late recurrence after curative resection of HBV-related hepatocellular carcinoma. Ann Surg Oncol, 2014,21(7):2429-2435. [34] Huang G, Lau WY, Zhou WP, et al. Prediction of Hepatocellular Carcinoma Recurrence in Patients With Low Hepatitis B Virus DNA Levels and High Preoperative Hepatitis B Surface Antigen Levels. JAMA Surg, 2014,149(6):519-527. [35] Papatheodoridi M, Tampaki M, Lok AS, et al. Risk of HBV reactivation during therapies for HCC: A systematic review. Hepatology, 2022,75(5):1257-1274. [36] Huang G, Lai EC, Lau WY, et al. Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels. Ann Surg, 2013,257(3):490-505. [37] Su YC, Lin PC, Yu HC, et al. Antiviral prophylaxis during chemotherapy or immunosuppressive drug therapy to prevent HBV reactivation in patients with resolved HBV infection: a systematic review and meta-analysis. Eur J Clin Pharmacol, 2018,74(9):1111-1119. [38] Seto WK, Chan TS, Hwang YY, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol, 2014,32(33):3736-3743. [39] Seto WK, Chan TS, Hwang YY, et al. Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study. Hepatology, 2017,65(5):1451-1461. [40] Huang G, Yang Y, Shen F, et al. Early viral suppression predicts good postoperative survivals in patients with hepatocellular carcinoma with a high baseline HBV-DNA load. Ann Surg Oncol, 2013,20(5):1482-1490. [41] Xu Y, Zhang YG, Wang X, et al. Long-term antiviral efficacy of entecavir and liver histology improvement in Chinese patients with hepatitis B virus-related cirrhosis. World J Gastroenterol, 2015,21(25):7869-7876. [42] Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-nave patients is rare through 5 years of therapy. Hepatology, 2009,49(5):1503-1514. [43] Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology, 2009,50(6):2001-2006. [44] Marcellin P, Wong DK, Sievert W, et al. Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection. Liver Int, 2019,39(10):1868-1875. [45] Hwang HS, Park CW, Song MJ. Tenofovir-associated Fanconi syndrome and nephrotic syndrome in a patient with chronic hepatitis B monoinfection. Hepatology, 2015,62(4):1318-1320. [46] Harkisoen S, Arends JE, Hoepelman AI, et al. Renal proximal tubular dysfunction due to tenofovir in a patient with chronic hepatitis B monoinfection. Clin Res Hepatol Gastroenterol, 2015,39(5):e67-69. [47] Gara N, Zhao X, Collins MT, et al. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther, 2012,35(11):1317-1325. [48] Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol, 2016,1(3):196-206. [49] Chan HL, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol, 2016,1(3):185-195. [50] Zand Irani M, Jones MP, Halland M, et al. Prevalence, symptoms and risk factor profile of rumination syndrome and functional dyspepsia: a population-based study. Aliment Pharmacol Ther, 2021,54(11-12):1416-1431. [51] Choi J, Kim HJ, Lee J, et al. Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study. JAMA Oncol, 2019,5(1):30-36. [52] Yip TC, Wong VW, Chan HL, et al. Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China. Gastroenterology, 2020,158(1):215-225.e6. [53] Choi J, Jo C, Lim YS. Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection. Hepatology, 2021,73(2):661-673. [54] Zhang M, Wang D, Liu H, et al. Tenofovir decrease hepatocellular carcinoma recurrence in chronic hepatitis B patients after liver resection. Infect Agent Cancer, 2018,13:19. [55] Xia Z, He L, Xiong L, et al. The comparison of different antiviral therapies on the prognosis of hepatitis B virus-related hepatocellular carcinoma after curative treatments: A network meta-analysis. Medicine (Baltimore), 2020,99(33):e20877. [56] 中华医学会肝病学分会肝炎学组,中华肝脏病杂志. 非一线核苷(酸)类似物经治慢性乙型肝炎患者治疗策略调整专家共识. 中华肝脏病杂志,2019,27(5):343-346. [57] Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol, 2008,8(7):559-568. [58] Ren P, Cao Z, Mo R, et al. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk. Expert Opin Biol Ther, 2018,18(10):1085-1094. [59] Li SY, Li H, Xiong YL, et al. Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: A five-year observational cohort study. J Viral Hepat, 2017,24 Suppl 1:12-20. [60] Zhang CH, Xu GL, Jia WD, et al. Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: a meta-analysis of randomized controlled trials. Int J Cancer, 2011,129(5):1254-1264. [61] Lo CM, Liu CL, Chan SC, et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg, 2007,245(6):831-842. [62] Chen LT, Chen MF, Li LA, et al. Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection. Ann Surg, 2012,255(1):8-17. [63] Lin SM, Lin CJ, Hsu CW, et al. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer, 2004,100(2):376-382. [64] Xu J, Li J, Chen J, et al. Effect of adjuvant interferon therapy on hepatitis b/c virus-related hepatocellular carcinoma after curative therapy-meta-analysis. Adv Clin Exp Med, 2015,24(2):331-340. [65] Yang S, Lin Q, Lin W, et al. Effect of adjuvant interferon therapy on hepatitis B virus-related hepatocellular carcinoma: a systematic review. World J Surg Oncol, 2016,14(1):159. [66] Zuo CH, Xia M, Liu JS, et al. Transcatheter arterial chemoembolization combined with interferon-α is safe and effective for patients with hepatocellular carcinoma after curative resection. Asian Pac J Cancer Prev, 2015,16(1):245-251. [67] Qi W, Zhang Q, Xu Y, et al. Peg-interferon and nucleos(t)ide analogue combination at inception of antiviral therapy improves both anti-HBV efficacy and long-term survival among HBV DNA-positive hepatocellular carcinoma patients after hepatectomy/ablation. J Viral Hepat, 2020,27(4):387-396. [68] 张文宏,张大志,窦晓光,等. 聚乙二醇干扰素α治疗慢性乙型肝炎专家共识. 中华肝脏病杂志,2017,25(9):678-686. [69] Wu D, Wang P, Han M, et al. Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study. Hepatol Int, 2019,13(5):573-586. [70] Ning Q, Han M, Sun Y, et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol, 2014,61(4):777-784. [71] Chan H, Chan F, Hui AJ, et al. Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir-A prospective study. J Viral Hepat, 2019,26(1):126-135. [72] Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 2018,68(2):723-750. [73] Kim H, Ahn SW, Hong SK, et al. Survival benefit of liver resection for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma. Br J Surg, 2017,104(8):1045-1052. [74] Zhang G, Yu X, Liu P, et al. Efficacy of Nucleoside Analogs for Chronic Hepatitis B Virus-Related Hepatocellular Carcinoma After Curative Treatment: A Meta-Analysis. Dig Dis Sci, 2018,63(12):3207-3219. [75] Xia BW, Zhang YC, Wang J, et al. Efficacy of antiviral therapy with nucleotide/nucleoside analogs after curative treatment for patients with hepatitis B virus-related hepatocellular carcinoma: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol, 2015,39(4):458-468. [76] Liu GM, Huang XY, Shen SL, et al. Adjuvant antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after curative treatment: A systematic review and meta-analysis. Hepatol Res, 2016,46(1):100-110. [77] Yuan P, Chen P, Qian Y. Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis. Can J Gastroenterol Hepatol, 2016,2016:5234969. [78] Chen XX, Cheng JW, Huang A, et al. The effect of antiviral therapy on patients with hepatitis B virus-related hepatocellular carcinoma after curative resection: a systematic review and meta-analysis. Onco Targets Ther, 2017,10:5363-5375. [79] Li Z, Lei Z, Xia Y, et al. Association of Preoperative Antiviral Treatment With Incidences of Microvascular Invasion and Early Tumor Recurrence in Hepatitis B Virus-Related Hepatocellular Carcinoma. JAMA Surg, 2018,153(10):e182721. [80] Zhang SS, Liu JX, Zhu J, et al. Effects of TACE and preventive antiviral therapy on HBV reactivation and subsequent hepatitis in hepatocellular carcinoma: a meta-analysis. Jpn J Clin Oncol, 2019,49(7):646-655. [81] Jang JW, Kim YW, Lee SW, et al. Reactivation of hepatitis B virus in HBsAg-negative patients with hepatocellular carcinoma. PLoS One, 2015,10(3):e0122041. [82] Chen VL, Yeh ML, Le AK, et al. Anti-viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virus-related hepatocellular carcinoma: real-world east and west experience. Aliment Pharmacol Ther, 2018,48(1):44-54. [83] Lu B, Zhu L, Wang X, et al. Effects of radiofrequency ablation combined with transarterial chemoembolization and antiviral therapy on the prognosis and quality of life in primary chronic HBV-related liver cancer. J BUON, 2019,24(5):1979-1984. [84] Wang X, Yang X, Chen F, et al. Hepatitis B Virus Reactivation Potential Risk Factors in Hepatocellular Carcinoma via Transcatheter Arterial Chemoembolization: A Retrospective Research. Can J Gastroenterol Hepatol, 2021,2021:8864655. [85] Wang K, Jiang G, Jia Z, et al. Effects of transarterial chemoembolization combined with antiviral therapy on HBV reactivation and liver function in HBV-related hepatocellular carcinoma patients with HBV-DNA negative. Medicine (Baltimore), 2018,97(22):e10940. [86] He MK, Le Y, Li QJ, et al. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study. Chin J Cancer, 2017,36(1):83. [87] Liu S, Lai J, Lyu N, et al. Effects of Antiviral Therapy on HBV Reactivation and Survival in Hepatocellular Carcinoma Patients Undergoing Hepatic Artery Infusion Chemotherapy. Front Oncol, 2020,10:582504. [88] Jun BG, Kim YD, Kim SG, et al. Hepatitis B virus reactivation after radiotherapy for hepatocellular carcinoma and efficacy of antiviral treatment: A multicenter study. PLoS One, 2018,13(7):e0201316. [89] Huang W, Zhang W, Fan M, et al. Risk factors for hepatitis B virus reactivation after conformal radiotherapy in patients with hepatocellular carcinoma. Cancer Sci, 2014,105(6):697-703. [90] Terrault NA, Lok A, McMahon BJ, et al. Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Clin Liver Dis (Hoboken), 2018,12(1):33-34. [91] Yang Y, Wen F, Li J, et al. A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib. Liver Int, 2015,35(9):2147-2154. [92] Lim S, Han J, Kim GM, et al. Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib. J Gastroenterol Hepatol, 2015,30(6):1024-1031. [93] Xu L, Gao H, Huang J, et al. Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib. J Gastroenterol Hepatol, 2015,30(6):1032-1039. [94] Ng K, Wong L, Ang A, et al. Real-world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: Experience of a tertiary Asian Center. Asia Pac J Clin Oncol, 2021,17(5):e249-249e261. [95] Fisicaro P, Valdatta C, Massari M, et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology, 2010,138(2):682-693, 693.e1-4. [96] Lee PC, Chao Y, Chen MH, et al. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J Immunother Cancer, 2020,8(2). [97] He MK, Peng C, Zhao Y, et al. Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis. Cancer Immunol Immunother, 2021,70(11):3207-3216. [98] Zhang X, Zhou Y, Chen C, et al. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition. J Immunother Cancer, 2019,7(1):322. [99] Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int, 2017,11(4):317-370. [100] Jeng WJ, Sheen IS, Chen YC, et al. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology, 2013,58(6):1888-1896. [101] Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. J Clin Oncol, 2020,38(31):3698-3715. [102] Sun Y, Wu X, Zhou J, et al. Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy. Clin Gastroenterol Hepatol, 2020,18(11):2582-2591.e6. [103] Kim JH, Sinn DH, Kang W, et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. Hepatology, 2017,66(2):335-343. [104] Ogawa E, Nomura H, Nakamuta M, et al. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B. Liver Int, 2020,40(7):1578-1589. |
| No related articles found! |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
